Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

Data from the LIBERTY AD PRESCHOOL trial, and its ongoing open-label extension analysis show that dupilumab is safe and clinically effective, and can lead to statistically significant symptom ...

Please provide your email address to receive an email when new articles are posted on . “We treat many children and adolescent patients with atopic dermatitis at Mount Sinai, and we saw an opportunity ...

Patients with prurigo nodularis (PN) who had severe itch and high lesion counts and whose condition was inadequately controlled with prior therapies experienced significant improvements with dupilumab ...

The results showed that 37.2% of patients in the dupilumab arm had at least a 4-point improvement in the patient-reported Worst-Itch Numerical Rating Scale (WI-NRS) at 12 weeks as compared with 22% of ...

The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is approved for atopic dermatitis in children aged 6 months and older. Patients on dupilumab did not ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- A new ...

Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ® ...

A registry-based study provides further evidence that treatment with dupilumab significantly reduces severity and symptoms of atopic dermatitis (AD) in clinical practice. Dupilumab also decreased ...

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...